Your single-source laboratory solution. FISH Probe Library

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Your single-source laboratory solution. FISH Probe Library"

Transcription

1 Your single-source laboratory solution. FISH Probe Library

2 Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC) 13q14 (DLEU) 20q (PTPRT) 21q ALK ATM BCL2 BCL6 CBFB, inv(16) CCND1 (CYCLIN D1) CCND1/IgH, t(11;14) CDKN2A (p16) (9p21) CKS1B (1p/1q ) Centromere 4 Enumeration Probe Centromere 6 Enumeration Probe Centromere 7 Enumeration Probe Centromere 8 Enumeration Probe Centromere 9 Enumeration Probe Centromere 10 Enumeration Probe Centromere 12 Enumeration Probe Centromere 15 Enumeration Probe Centromere 17 Enumeration Probe DDIT3 (CHOP) EGFR ETV6/RUNX1 (TEL/AML), t(12;21) EWSR1 FGFR1 Follicular lymphoma, Oligodendroglioma AML, MDS AML, MDS, MPN, CLL, MDS, MPN MDS, MPN B-ALL (adult), AML, T-cell anaplastic lymphoma CLL B-ALL (adult and pediatric), AML, CML AML CLL, Mantle cell lymphoma, CLL, Mantle cell lymphoma, B-ALL (adult), Melanoma MDS, MPD, MPN MPN, CLL Myxoid/Round cell liposarcoma Glioma, B-ALL, iamp ALL Ewing sarcoma, PNET 1

3 Probe Clinical Indication FGFR3/IGH, t(4;14) FOXO1 (FKHR) HER2 IGH IGH/BCL2, t(14;18) IGH/MAF, t(14;16) IGH/MYC, t(8;14) MALT1, t(11;18) MECOM (EVI1) MET MYB MYC MYCN PDGFRA PDGFRB PML/RARA, t(15;17) PTEN RARA RB1 (13q14) RET ROS1 RREB1 RUNX1T1/RUNX1 (ETO/AML), t(8;21) SS18 (SYT) TCF3 (E2A) TCR TP53 (17p deletion) UroVysion XX/XY Alveolar rhabdomyosarcoma Breast, Gastric cancer B-cell lymphoma Burkitt lymphoma, High grade B-cell lymphoma B-ALL (adult and pediatric), AML Marginal zone lymphoma AML, MDS Melanoma Burkitt lymphoma, High grade B-cell lymphoma Neuroblastoma APL Glioma APL Retinoblastoma Melanoma AML Synovial sarcoma T-cell leukemia AML, CLL, MDS, Bladder cancer Bone marrow transplant *includes Multiple myeloma and MGUS 2

4 Hematology/Oncology Profiles Disease Probes Included B-ALL (Adult) B-ALL (Pediatric) AML CLL MDS MPN/CML MPN with Eosinophilia Multiple Myeloma Aggressive B-cell Lymphoma 21q Chromosome 6 MYC CDKN2A (p16) Centromere 4 Centromere 10 Centromere 17 ETV6/RUNX1, t(12;21) TCF3 (E2A) 5q 7q CBFB, inv(16) PML/RARA, t(15;17) RUNX1T1/RUNX1, t(8;21) 13q14 (DLEU) ATM (11q) CCND1/IGH, t(11;14)** Centromere 12 TP53 (17p) 5q 7q 20q Centromere 8 13q14 (DLEU) 20q CDKN2A (Centromere 9) Centromere 8 FGFR1 PDGFRA PDGFRB 13q14 (DLEU) CCND1/IGH, t(11;14) Centromere 7 Centromere 9 Centromere 15 CKS1B (1q21) FGFR3/IGH, t(4;14) IGH/MAF, t(14;16) TP53 (17p) BCL2 BCL6 MYC **used as differential 3

5 Solid Tumor Probes Disease Probe Breast Cancer HER2 Bladder Cancer UroVysion Colorectal Cancer Gastric Cancer Glioma Lung Cancer (Non-Small Cell) Melanoma Neuroblastoma Retinoblastoma EGFR HER2 1p/19q EGFR PTEN ALK MET RET ROS1 CCND1 Centromere 6 MYB RREB1 MYCN RB1 (13q14) Sarcomas Ewing Sarcoma Alveolar Rhabdomyosarcoma Synovial Sarcoma Myxoid/Round Cell Liposarcoma EWSR1 FOXO1 (FKHR) SS18 (SYT) DDIT3 (CHOP) 4

6 Probes Suitable for FFPE Specimens Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) ALK BCL2 BCL6 CBFB, inv(16) CCND1 (CYCLIN D1) CCND1/IgH, t(11;14) DDIT3 (CHOP) EGFR ETV6/RUNX1 (TEL/AML), t(12;21) EWSR1 FOXO1 (FKHR) HER2 IGH IGH/BCL2, t(14;18) IGH/MYC, t(8;14) MALT1, t(11;18) MET MYC MYCN PDGFRA PDGFRB PTEN RB1 (13q14) RET ROS1 SS18 (SYT) TCR XX/XY Follicular lymphoma, Oligodendroglioma, T-cell anaplastic lymphoma B-ALL (adult and pediatric), CML AML CLL, Mantle cell lymphoma, CLL, Mantle cell lymphoma, Myxoid/Round cell liposarcoma Glioma, B-ALL Ewing sarcoma, PNET Alveolar rhabdomyosarcoma Breast, Gastric cancer B-cell lymphoma Follicular lymphoma Burkitt lymphoma, High grade B-cell lymphoma B-ALL (adult and pediatric), AML Marginal zone lymphoma Burkitt lymphoma, High grade B-cell lymphoma Neuroblastoma Glioma Retinoblastoma Synovial sarcoma T-cell leukemia Bone marrow transplant Formalin-fixed, paraffin-embedded *includes Multiple myeloma and MGUS 5

7 Specimen Requirements Type Preferred Alternate Blood Optimal: 10 ml (adult) or 3-5 ml (pediatric) in green-top (heparin) tube Acceptable: Lavender-top (EDTA) tube Bone Marrow Optimal: 1-3 ml in green-top (heparin) tube Fixed-cell pellet from cytogenetic analysis Slides prepared from a cytogenetic analysis Fixed-cell pellet from cytogenetic analysis Acceptable: Lavender-top (EDTA) tube Slides prepared from a cytogenetic analysis Tissue Formalin-fixed, paraffin-embedded (FFPE) tissue block 4-5 unstained slides, cut to 4-5 microns thick, air-dried overnight Specimens should be maintained at room temperature. For more specific specimen requirements for individual tests, please refer to 6

8 Integrated Oncology your single-source laboratory solution. More than 490,000 tests performed on 225,000+ patients annually 1,600 contractual relationships with plans, payors, and other health care organizations across the US, some of which are on an exclusive basis Integrated with more than 700 electronic medical records (EMR) and practice management systems Menu of more than 450 genetic, pathology, IHC, and FISH tests, including 15 oncology-specific pharmacogenetic tests Staff of more than 75 pathologists, PhDs, and genetic counselors dedicated to oncology and familial cancer testing More than 65 oncology- and pathology-specific publications and presentations since 2013 Lab Locations Arizona Integrated Oncology 5005 South 40th Street Phoenix, AZ Fax New York Integrated Oncology 521 West 57th Street, Sixth Floor New York, NY Fax North Carolina LabCorp Center for Molecular Biology and Pathology 1912 Alexander Drive Research Triangle Park, NC Fax Tennessee Integrated Oncology 201 Summit View Drive, Suite 100 Brentwood, TN Fax access answers actions UroVysion is a registered trademark of Abbott Laboratories, Inc Laboratory Corporation of America Holdings. All rights reserved. onc-017-v L

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING INTRODUCTION The Cytogenetics Laboratory offers a comprehensive array of chromosome investigations for cancers, constitutional abnormalities, and prenatal and postnatal diagnosis. Analyses are performed

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically

More information

molecular oncology services

molecular oncology services Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease

More information

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy. Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine

More information

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6 Page 1 of 6 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostic Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 Patient

More information

The Center for PERSONALIZED DIAGNOSTICS

The Center for PERSONALIZED DIAGNOSTICS The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000

More information

Haematology Probes for Multiple Myeloma

Haematology Probes for Multiple Myeloma Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex

More information

Chapter 2 Classical and Molecular Cytogenetic Analysis of Hematolymphoid Disorders

Chapter 2 Classical and Molecular Cytogenetic Analysis of Hematolymphoid Disorders Chapter 2 Classical and Molecular Cytogenetic Analysis of Hematolymphoid Disorders Mark A. Micale Keywords Myelodysplastic/myeloproliferative disorders Leukemia Lymphoma Fluorescence in situ hybridization

More information

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

GENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the author to give readers additional information about his work. Supplement to: Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11.

More information

Introducing Western Diagnostic s Genomic Pathology

Introducing Western Diagnostic s Genomic Pathology Genetic Testing Introducing Western Diagnostic s Genomic Pathology As one of Australia s longest running and nationally coordinated DNA testing organisations, Western Diagnostic s Genomic Pathology perform

More information

Molecular Hematopathology

Molecular Hematopathology Molecular Hematopathology Charles E. Hill, MD, PhD Emory University School of Medicine April 2013 The Association for Molecular Pathology Education. Innovation and Improved Patient Care. Advocacy. www.amp.org

More information

UTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES

UTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES UTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES S Schwartz, Z Hosseini, S Schepis, P Papenhausen Laboratory Corporation of America

More information

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran

More information

Molecular Pathology of Sarcomas: Diagnostic and Therapeutic Utility. Meera Hameed MD

Molecular Pathology of Sarcomas: Diagnostic and Therapeutic Utility. Meera Hameed MD Molecular Pathology of Sarcomas: Diagnostic and Therapeutic Utility Meera Hameed MD Role of a Pathologist Custodians and Curators of tumor diagnostic specimens Appreciation of Pathogenesis Determination

More information

MOLECULAR SERVICES. mlabs.umich.edu

MOLECULAR SERVICES. mlabs.umich.edu MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service

More information

HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry

HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING The 2008 WHO classification system for tumors of hematopoietic and lymphoid tissues specifies that various combinations of immunophenotypic

More information

Cardiovascular Molecular Cytogenetics Methylenetetrahydrofolate Oligodendrogliomas Reductase (MTHFR) Mutation SS18 (C677T & A1298C) QF-PCR Sample:

Cardiovascular Molecular Cytogenetics Methylenetetrahydrofolate Oligodendrogliomas Reductase (MTHFR) Mutation SS18 (C677T & A1298C) QF-PCR Sample: Genetics Testing Dorevitch Pathology offers a comprehensive range of molecular and cytogenetic tests covering a wide spectrum of clinical indications to help in the diagnosis, management and treatment

More information

Initial Diagnostic Workup of Acute Leukemia

Initial Diagnostic Workup of Acute Leukemia Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine

More information

Genet Med advance online publication 28 April 2016

Genet Med advance online publication 28 April 2016 American College of Medical Genetics and Genomics ACMG Standards and Guidelines Section E6.1 6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow acquired

More information

GENOPTIX DELIVERS CLEAR, COMPREHENSIVE, AND CLINICALLY ACTIONABLE RESULTS

GENOPTIX DELIVERS CLEAR, COMPREHENSIVE, AND CLINICALLY ACTIONABLE RESULTS TESTING DIRECTORY APRIL 2017 GENOPTIX DELIVERS CLEAR, COMPREHENSIVE, AND CLINICALLY ACTIONABLE RESULTS Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA 92008 Phone: 760.268.6200 Fax: 760.268.6201

More information

American Society of Cytopathology Core Curriculum in Molecular Biology

American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 1 Molecular Basis of Cancer Molecular Oncology Keisha

More information

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for

More information

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back... Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR

More information

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms Molecular Diagnostics of Myeloid and Lymphoid Neoplasms Molecular Pathology: Principles in Clinical Practice - 2012 John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

An introduction to the Essential Medicines concept: balancing innovation with public health priorities

An introduction to the Essential Medicines concept: balancing innovation with public health priorities An introduction to the Essential Medicines concept: balancing innovation with public health priorities World Oncology Forum Lugano 20 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the

More information

Molecular Probes Introducing 14 new probes

Molecular Probes Introducing 14 new probes Molecular Probes Introducing 14 new probes Gene and Chromosome Probes Dual Colour ISH INFORM HER2 Dual ISH DNA Probe Cocktail Assay Product Part Number INFORM HER2 Dual ISH DNA Probe Cocktail 800-4422

More information

Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository ( ) for cancer in Teenagers and Young Adults

Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository ( ) for cancer in Teenagers and Young Adults Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository (2007 09) for cancer in Teenagers and Young Adults (TYA) CTYA SSCRG Data quality report on the frequency

More information

Test Utilization: Chronic Lymphocytic Leukemia

Test Utilization: Chronic Lymphocytic Leukemia Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.

More information

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:

More information

Hematology Page 1 of 8

Hematology Page 1 of 8 Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340

More information

Lymphoma: The Basics. Dr. Douglas Stewart

Lymphoma: The Basics. Dr. Douglas Stewart Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

Myeloma Genetics what do we know and where are we going?

Myeloma Genetics what do we know and where are we going? in partnership with Myeloma Genetics what do we know and where are we going? Dr Brian Walker Thames Valley Cancer Network 14 th September 2015 Making the discoveries that defeat cancer Myeloma Genome:

More information

Heme fusion assay. Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School

Heme fusion assay. Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School Heme fusion assay Valentina Nardi, MD Assistant pathologist Massachusetts General Hospital Assistant Professor Harvard Medical School No personal disclosures/conflicts of interest Kinase fusions in solid

More information

Follicular Lymphoma: the WHO

Follicular Lymphoma: the WHO Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure

More information

Change Summary - Form 2018 (R3) 1 of 12

Change Summary - Form 2018 (R3) 1 of 12 Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

Gliomas in the 2016 WHO Classification of CNS Tumors

Gliomas in the 2016 WHO Classification of CNS Tumors Gliomas in the 2016 WHO Classification of CNS Tumors Hindi N Al-Hindi, MD, FCAP Consultant Neuropathologist and Head Section of Anatomic Pathology Department of Pathology and Laboratory Medicine King Faisal

More information

Integrated Hematopathology. Morphology and FCI with IHC

Integrated Hematopathology. Morphology and FCI with IHC Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,

More information

Chapter 4 Cellular Oncogenes ~ 4.6 -

Chapter 4 Cellular Oncogenes ~ 4.6 - Chapter 4 Cellular Oncogenes - 4.2 ~ 4.6 - Many retroviruses carrying oncogenes have been found in chickens and mice However, attempts undertaken during the 1970s to isolate viruses from most types of

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

The Lymphomas. Dr. G Errico Haematology SpR Royal Hallamshire Hospital

The Lymphomas. Dr. G Errico Haematology SpR Royal Hallamshire Hospital The Lymphomas Dr. G Errico Haematology SpR Royal Hallamshire Hospital Overview Lymphoma Where does it come from? How does it present? How is it diagnosed? How do we treat it? What is the outcome? Where

More information

Collected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS

Collected: , PM Sent: , PM Received: , PM Preliminary: , PM. Notification Status: COMPREHENSIVE DIAGNOSIS PATIENT Name:HIPAA, Compliant DOB: 03-25-1945 (60 yr) ID#: xxx-xx-0000 Sex: M Tel: xxx-xxx-xxxx SPECIMEN Your No:WS05-xxxx Case No:C05-00xxx Req. No:Txxxxx Collected: 06-08-05, PM Sent: 06-09-05, PM Received:

More information

Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas

Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor

More information

PD-L1 Analyte Control DR

PD-L1 Analyte Control DR Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1

More information

Successful flow cytometric immunophenotyping of body fluid specimens

Successful flow cytometric immunophenotyping of body fluid specimens Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Hematologic Malignancies. Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine

Hematologic Malignancies. Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Hematologic Malignancies Eunice S. Wang MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan C et

More information

Oncology Genetics: Cytogenetics and FISH 17/09/2014

Oncology Genetics: Cytogenetics and FISH 17/09/2014 Oncology Genetics: Cytogenetics and FISH 17/09/2014 Chris Wragg Head of Oncology Genomics, BGL BGL Bristol Genetics Laboratory (BGL) CPA accredited Genetics laboratory serving a core population of 4-5million

More information

UCL-Advanced Diagnostics. 2015/16 Service Update

UCL-Advanced Diagnostics. 2015/16 Service Update UCL-Advanced Diagnostics 2015/16 Service Update About UCL-Advanced Diagnostics UCL Advanced Diagnostics (UCL-AD) is the immunohistochemistry, in situ and molecular diagnostics service arm of the UCL-Cancer

More information

Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology

Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Ugur Ozerdem, M.D. 1 Abstract Background: There is a paradigm shift in breast biopsy philosophy. In

More information

What s New in Dermatopathology Melanocytic proliferations

What s New in Dermatopathology Melanocytic proliferations What s New in Dermatopathology Melanocytic proliferations Aleodor (Doru) Andea, MD, MBA Associate Professor of Pathology and Dermatology Director of Dermatopathology Molecular Diagnostic Laboratory University

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia

More information

Registration & Shipment Manual

Registration & Shipment Manual Registration & Shipment Manual INFORM INdividualized Therapy FOr Relapsed Malignancies in Childhood Coordinating Investigator Registry: Prof. Dr. med. Olaf Witt NCT Clinical Trial Center Heidelberg Dr.

More information

What is the status of the technologies of "precision medicine?

What is the status of the technologies of precision medicine? Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.

More information

The French national network of 28 hospital molecular genetics platforms: summary of the activity in 2009

The French national network of 28 hospital molecular genetics platforms: summary of the activity in 2009 Measure 21 care and life of patients The French national network of 28 hospital molecular genetics platforms: summary of the activity in 2009 COLLECTION reports & summaries ACCESS TO INNOVATIVE MOLECULAR

More information

Prior Authorization Required: Additional Information:

Prior Authorization Required: Additional Information: Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below No A first-degree relative is defined as an individual

More information

Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities

Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid

More information

NEW IHC A n t i b o d i e s

NEW IHC A n t i b o d i e s NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology

More information

Lymphoma 101. Harold J. Olney, MD, FRCPC Montreal, September 2017

Lymphoma 101. Harold J. Olney, MD, FRCPC Montreal, September 2017 Lymphoma 101 Harold J. Olney, MD, FRCPC Montreal, September 2017 Declaration of potential conflit of interests Have received honorarium as advisor and/or speaker for : Amgen Bristol Myers Squibb Celgene

More information

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,

More information

MOC HEM - General Hematopathology (Mandatory 50-Question Module)

MOC HEM - General Hematopathology (Mandatory 50-Question Module) MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes

More information

MOC HEM - General Hematopathology (Mandatory 50-Question Module)

MOC HEM - General Hematopathology (Mandatory 50-Question Module) MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes

More information

Hodgkin and Non-Hodgkin Lymphoma Post-HCT

Hodgkin and Non-Hodgkin Lymphoma Post-HCT (Form 2118) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Post-HCT Form. E-mail comments regarding the content of

More information

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy?

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION

More information

Non-Hodgkin s Lymphomas Version

Non-Hodgkin s Lymphomas Version NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell

More information

Human cell line list Production of Exosome Standards - Cell Lysates

Human cell line list Production of Exosome Standards - Cell Lysates Human cell line list 2016 - Production of Exosome Standards - Cell Lysates 380 peripheral blood leukemia, pre-b cell 1301 blood leukemia, acute lymphoblastic, T cell 5637 bladder carcinoma 8305C thyroid

More information

I. Leukemias: II. Lymphomas Hodgkin Lymphomas: Proprietary Information of Excellus Health Plan, Inc.

I. Leukemias: II. Lymphomas Hodgkin Lymphomas: Proprietary Information of Excellus Health Plan, Inc. MEDICAL POLICY SUBJECT: AUTOLOGOUS HEMATOPOIETIC PAGE: 1 OF: 13 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Hematopathology Service Memorial Sloan Kettering Cancer Center, New York

Hematopathology Service Memorial Sloan Kettering Cancer Center, New York SH2017-0334 t(14;18) Negative Follicular Lymphoma with 1p36 abnormality associated with In Situ Follicular Neoplasia with t(14;18) translocation Pallavi Khattar MD, Jennifer Maerki MD, Alexander Chan MD,

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017 LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer

More information

El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD

El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression

More information

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam: Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist

More information

Lymphoblastic Leukemia / Lymphoma

Lymphoblastic Leukemia / Lymphoma 1 5014 - Topics in Pediatric Hematopathology: Acute Lymphoblastic Leukemia, Including Changes in the Revised WHO Classification, and Unusual Pediatric Myeloid Neoplasms Robert W. McKenna, MD MASCP * Elizabeth

More information

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor

More information

NCCN National Comprehensive Cancer Network Directory Information

NCCN National Comprehensive Cancer Network Directory Information Please provide the information requested below. The information contained herein is for NCCN purposes only and will not be published without your express written consent below. Name: Last First Middle

More information

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases

Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases International Journal of Research in Medical Sciences Patel A et al. Int J Res Med Sci. 2015 Dec;3(12):3833-3839 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151452

More information

June Monthly Update, Quest Diagnostics Nichols Institute, Valencia

June Monthly Update, Quest Diagnostics Nichols Institute, Valencia June 2013 - Monthly Update, NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test

More information

Case 1. Disclosure. Imaging. Clinical history 5/10/2016. USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology

Case 1. Disclosure. Imaging. Clinical history 5/10/2016. USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology Disclosure Dr. Agaram has nothing to disclose Case 1 Narsi Agaram, MBBS USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology Clinical history Imaging 1998 A three month

More information

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1 Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation December 2012 Reference : NHSCB/B4/a/1 NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation

More information

Head and Neck: DLBCL

Head and Neck: DLBCL Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD

More information

Oncology Drug Development

Oncology Drug Development Oncology Drug Development Advantages and challenges of using stratified clinical studies Simon J Hollingsworth The 18th Anti-Tumour Drug Development Forum 21 February Japan Stratified Medicine In The Clinic

More information

Classification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases

Classification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases Immunohistochemical classification of haematolymphoid tumours Haematolymphoid Neoplasias: Leukaemia vs Lymphoma C L O N A L M A L I G N A N C I E S Stephen Hamilton-Dutoit Institute of Pathology Aarhus

More information

ACTIVITY 2: EXAMINING CANCER PATIENT DATA

ACTIVITY 2: EXAMINING CANCER PATIENT DATA OVERVIEW Refer to the Overview of Cancer Discovery Activities for Key Concepts and Learning Objectives, Curriculum Connections, and Prior Knowledge, as well as background information, references, and additional

More information

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,

More information

5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach

5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach 5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach Joseph A DiGiuseppe, MD, PhD Hartford Hospital Disclosures In the past 12 months, I have

More information

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer

HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment

More information

A tumor profile and adapted cancer surveillance in Down syndrome

A tumor profile and adapted cancer surveillance in Down syndrome A tumor profile and adapted cancer surveillance in Down syndrome Daniel Satgé Pathology, University Hospital, Saint Etienne, France and ONCODEFI Project IURC Montpellier, France Michel Vekemans Labratory

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr. BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:

More information

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential

More information

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director

Tumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer

More information

FINALIZED SEER SINQ S NOVEMBER 2011

FINALIZED SEER SINQ S NOVEMBER 2011 : 20110133 Multiple primaries/heme & Lymphoid Neoplasms: A patient was diagnosed 7/31/08 with DLBCL (9680/3) (biopsy left supraclav. node), stage IIIB. Treated with chemo. 10/14/10 biopsy right supraclav.

More information